Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29859758 | 1.00 | NOTUM (0.60) | NOTUMDRD2DRD4TP53LMNA | |
| SCHEMBL2827512 | 1.00 | NOTUM (0.60) | NOTUMDRD2DRD4TP53LMNA | |
| SCHEMBL2827516 | 1.00 | NOTUM (0.60) | NOTUMDRD2DRD4TP53LMNA | |
| SCHEMBL17442799 | 0.88 | DRD2 (0.55) | NOTUMDRD2DRD4LMNA | |
| SCHEMBL2824164 | 0.84 | NOTUM (0.56) | NOTUMDRD2DRD4TP53ALDH1A1 | |
| SCHEMBL2824161 | 0.84 | NOTUM (0.56) | NOTUMDRD2DRD4TP53ALDH1A1 | |
| SCHEMBL16350248 | 0.84 | NOTUM (0.68) | NOTUMTP53 | |
| SCHEMBL4707127 | 0.84 | NOTUM (0.68) | NOTUMTP53 | |
| SCHEMBL2827018 | 0.83 | DRD2 (0.51) | NOTUMDRD2DRD4LMNA | |
| SCHEMBL29442998 | 0.83 | DRD2 (0.51) | NOTUMDRD2DRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034051-B2 | Fused bicyclic carboxamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 | NOTUM 407/4885DRD2 1588/4885DRD4 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.